Drugnews

What Medicare price benchmark does BEQIA face against Eliquis?

For 2026, Medicare’s negotiated price for a 30-day Eliquis (apixaban) supply is US$231, compared with the 2023 list price of US$521, a rounded 56% reduction. Drugnews’s November 5, 2026 analysis uses this CMS benchmark to discuss the pricing environment for TAHO Pharmaceuticals’ BEQIA oral film; the figures do not set BEQIA’s own price.

Updated

CMS Eliquis benchmark, effective January 1, 2026
MeasureReported resultBasis
Negotiated Medicare priceUS$23130-day equivalent supply
Comparator list priceUS$5212023 list price; same 30-day supply
CMS rounded reduction56%Negotiated price compared with that list price

The comparison is not a discount from a current net price, a retail cash quote, or a proposed BEQIA price.

Sources

Read the full analysis

TAHO Doubles in Two Weeks, but a Court Holds Its US Clock — 2026-11-05